Healthcare is one of the world’s sectors that are growing at a fast rate. Some of the areas within healthcare are expected to expand at rates, which are plainly out of the charts. Health care management is one of the fields that hold the top position in the healthcare industry for its ability to offer job stability and greater earning potential. Scott M. Rocklage is one of the individuals who has set an outstanding record of accomplishments in the arena of healthcare management. His unmatched experience coupled with strategic leadership opportunities have resulted in the licensing of three new drug applications, Cubicin, Omniscan, and Teslascan, by the U.S. FDA. He has also managed to enter six drugs into clinical stages.
Rocklage is a proud alumnus of the prominent University of California and holds an undergrad in chemistry. He earned his Ph.D. in chemistry from the prestigious MIT where he carried out his research in the Richard R. Schrock’s laboratory. Dr. Rocklage is a developer or a co-developer of more than 30 U.S. patents and has over 100 peer-reviewed published research papers.
Rocklage secured a high-status entry into the 5 AM Ventures in the capacity of venture partner in 2003. His commitment, research abilities, and exceptional leadership paid off and, within a year, he ascended to the managing partner position. Dr. Rocklage has served in many prominent firms as a healthcare management executive. For instance, he was the chairperson and chief executive of Cubist Pharmaceuticals, Relypsa’s board chairman, president and managing principal of Nycomed Salutar. He has also served at Catalytica and Salutar.
Dr. Rocklage previously sat on the Board of Governance of Relypsa and Novisa as the chairman. He is the current Board Chair of Kinestral, Epirus, Pulmatrix, Cidara, and Rennovia. He is the former executive director of healthcare firms such as Ilypsa, Semprus, and Milkana.
Dr. Rocklage loves donating toward philanthropic causes that aim at improving life. He donated heavily towards the advancement of scientific research. He recently joined forces with Patty, his wife, to pledge $250,000 to finance the renovations of MIT’s nanotechnology and nanochemistry lab space.
An overview on 5 AM Ventures
5 AM Ventures is a premier venture capital company that specializes on establishing state-of-the-art life science firms with the ability to deliver exceptional revenues to its investors. The company offers unwavering support to companies, which are striving to find long-lasting solutions to pressing healthcare problems through groundbreaking breakthroughs in the fields of medicine and science. Its portfolio companies lead with unique tactics for diagnosing, preventing, and treating an extensive collection of medical conditions. 5 AM’s talented investment professionals boast superior scientific, operational, finance, legal, and medical expertise. The firm’s team utilizes time-tested, practical strategy for company building.